Anti-CTLA-4 Antibodies Modulate Immune Checkpoint Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective methods to modulate CTLA-4 activity, which is crucial for regulating T cell activation and immune responses, particularly in treating cancers and viral infections.

Innovation Solution

Development of antibodies and antigen-binding fragments that specifically bind to CTLA-4, allowing for the modulation of its activity. These antibodies can inhibit or neutralize CTLA-4 activity, stimulate T cell activation, and target specific cell types such as tumor cells or infected cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CTLA-4 binds to B7 ligands with high affinity to inhibit T cell activation, then immune response regulation is improved, but therapeutic efficacy against cancer and viral infections deteriorates

Engineering Contradiction:

Improveimmune response regulationVSAvoidtherapeutic efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent introduces antibodies as intermediary molecules that bind to CTLA-4 and block its interaction with B7 ligands. These antibodies serve as mediators that prevent the inhibitory signaling pathway while preserving the natural immune regulation mechanism, thereby enhancing therapeutic efficacy without compromising immune response regulation

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the binding parameters of the CTLA-4/B7 interaction by introducing antibodies with specific affinity characteristics. By changing the binding parameters through antibody selection and engineering, the inhibitory effect of CTLA-4 is modulated to achieve optimal therapeutic outcomes while maintaining immune regulation

Inventive Principle:

Principle #35Parameter changes

2Productivity

If CD28 competes with CTLA-4 for B7 ligands to stimulate T cell activation, then T cell response is improved, but immune checkpoint control deteriorates

Engineering Contradiction:

ImproveT cell responseVSAvoidimmune checkpoint control

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies partial action by using antibodies that partially block CTLA-4/B7 interaction rather than completely eliminating it. This partial blockade enhances T cell response while preserving sufficient immune checkpoint control to prevent autoimmunity and maintain immune homeostasis

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibodies effectively inhibit CTLA-4 activity, enhance T cell activation, and have therapeutic potential in treating cancers and viral infections by promoting immune responses.

Implementation Method 1

antibodies and antigen-binding fragments that specifically bind to CTLA-4

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS20250122307A1Anti-CTLA-4 Antibodies and Uses Thereof

Publication Date: 2025.04.17 REGENERON PHARMACEUTICALS INC

AI summary

The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.